The rise of copyright’s blockbuster initially fueled a surge for pharma, however recent developments present a complicated scenario for those considering a stake. Off-patent versions are reducing profits, and ongoing litigation add more complexity to the situation. While specific companies might still see gains from complementary services, the g… Read More